Vantrexa · NSCLC · Japan · Oncology pharmacist · captured by Mei Tanaka on 24 Mar 2026 · reviewed by Dr. Priya Raman on 30 Mar 2026
Marked as duplicate
Verbatim as captured; never edited
Oncology pharmacist at National Cancer Center Tokyo raised chemotherapy-free first line during a payer / hta meeting. They requested supporting literature and a follow-up discussion.
Human-approved by Dr. Priya Raman on 30 Mar 2026
Chemotherapy-free first line: request for data reported by oncology pharmacist (JP).
No AI assistance
Transparent weighted model; contribution = value ÷ 5 × weight
| Dimension | Value (1–5) | Weight | Contribution |
|---|---|---|---|
| Patient relevance | 4 | 20% | 16.0 |
| Strategic alignment | 5 | 20% | 20.0 |
| Scientific importance | 4 | 15% | 12.0 |
| Urgency | 1 | 15% | 3.0 |
| Novelty | 4 | 10% | 8.0 |
| Actionability | 3 | 10% | 6.0 |
| Confidence | 3 | 5% | 3.0 |
| Breadth of occurrence | 3 | 5% | 3.0 |
| Total | High 71 | ||
| Time | Action | User | Field | Change | Reason | Source |
|---|---|---|---|---|---|---|
| 07 Sept 2026, 18:39 UTC | Update | ABDr. Anna Becker | summary | In progress → Reviewed | — | Integration |
Every model call on this record and its human outcome
No AI interactions in sample data
Current stage and the next allowed action
Who reviewed, what action, which function, what decision, what outcome, when closed
22 Mar 2026 · Dr. Sven Nakamura, National Cancer Center Tokyo · MSL Mei Tanaka
Insight
Reviewed 30 Mar 2026 by Dr. Priya Raman
Action
Medical education program · Dr. Sophie Laurent · In progress
Decision
Outcome
Closure
Incorporated into evidence-generation plan.
Duplicate of INS-0047 — Multiple US academic centres are reluctant to use vantrelimab in patients with asymptomatic brain metastases because VOYAGE-1 excluded untreated CNS disease. Absence of subgroup or real-world data drives default to chemo-immunotherapy.